Trials / Completed
CompletedNCT04173637
Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized, Double-blinded, Placebo-controlled, Phase IIb Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 330 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multiple-center, randomized, double-blind, placebo-controlled Phase IIb study to evaluate the efficacy and safety of AK101, an anti-IL-12/23 p40 antibody, when administered subcutaneously, in subjects with moderate-to-severe plaque psoriasis. The study will consist of 3 periods: up to 4 weeks screening, 12 weeks double-blinded treatment and long-term follow-up period(up to 52 weeks).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AK101 | an anti-IL-12/23p40 monoclonal antibody |
| BIOLOGICAL | Placebo | matching placebo |
Timeline
- Start date
- 2019-12-19
- Primary completion
- 2022-03-03
- Completion
- 2022-03-03
- First posted
- 2019-11-22
- Last updated
- 2025-02-28
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04173637. Inclusion in this directory is not an endorsement.